Researchers at Weill Cornell Medicine and the Burke Neurological Institute have made an exciting discovery—a new drug that ...

The FDA has placed a trial of Rapport Therapeutics’ epilepsy drug for a type of nerve pain on hold while the biotech tweaks ...

The Phase III trial AV001 aims to evaluate QUTENZA ® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical ...

"Patients who undergo surgery and end up developing post-surgical neuropathic pain, may experience debilitating complications that often are not treated appropriately," says Lizandra Marcondes, M.D., ...

Conditions such as diabetes or nerve injury can cause neuropathic pain, which is often long lasting and has a major impact on quality of life. It is difficult to treat because the underlying factors ...

Cannabidiol (CBD) holds great promise as a treatment for many health concerns, including inflammation. For all the known benefits CBD offers, it’s unclear how well it can relieve nerve pain.

Neuropathic pain is a chronic and debilitating condition that impacts around 10% of the population in both the United States and Europe. Despite advances in understanding the mechanisms of neuropathic ...

Neuropathic pain is a severe clinical condition caused ... Currently, there are no effective treatments for this devastating condition because the clinical presentation varies from person to ...

Neuropathic pain is a severe clinical condition caused by damage to the nervous system. It often feels like a burning, shooting, tingling ice or stabbing sensation. Conditions such as diabetes or ...

Promising Preclinical Results Position Ketamir-2 as a Potential Breakthrough Therapy That Surpasses Current Treatments, With Results to Be Presented at the Pain Therapeutics Summit in Boston MIAMI, FL ...

秋风送爽，丹桂飘香。近日（9月19日-22日），由中华医学会、中华医学会神经病学分会主办，河南省医学会承办的“中华医学会第二十七次神经病学学术会议”在美丽的郑州顺利召开。国内外知名专家学者齐聚，共享学术饕餮盛宴。神经病理性疼痛（NP）指由躯体感觉系统 ...

FREEHOLD, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced the ...